ReviewDiscovery medicine2012
T cell coinhibition and immunotherapy in human breast cancer.
Review in Discovery medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Immune checkpoint biology in hepatocellular carcinoma (Review).Oncology letters · 2025Review
- The prognostic genes model of breast cancer drug resistance based on single-cell sequencing analysis and transcriptome analysis.Clinical and experimental medicine · 2024Article
- Enabling continuous immune cell recirculation on a microfluidic array to study immunotherapeutic interactions in a recapitulated tumour microenvironment.Lab on a chip · 2024Article
- Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report.Journal of medical case reports · 2023Article
- A prognostic model related to necrotizing apoptosis of breast cancer based on biorthogonal constrained depth semi-supervised nonnegative matrix decomposition and single-cell sequencing analysis.American journal of cancer research · 2023Article
- Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells.Journal of clinical medicine · 2019Review
- Review: Bioengineering strategies to probe T cell mechanobiology.APL bioengineering · 2018Review
- Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- In-vitro effect of pembrolizumab on different T regulatory cell subsets.Clinical and experimental immunology · 2018Article
- The association betweenBioscience reports · 2017Article
- The molecular basis of breast cancer pathological phenotypes.The Journal of pathology · 2017Article
- Altered expression of miR-181a and miR-146a does not change the expression of surface NCRs in human NK cells.Scientific reports · 2017Article
- HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Relationship Between PD-L1 Expression and Clinical Characteristics in Patients with Breast Invasive Ductal Carcinoma.Open medicine (Warsaw, Poland) · 2017Article
- Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.Oncotarget · 2016Article
- Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway.Cancer cell international · 2015Article
- Structure and cancer immunotherapy of the B7 family member B7x.Cell reports · 2014Article
- PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients.Cancer immunology, immunotherapy : CII · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Costimulation and coinhibition generated by the B7 family and their receptor CD28 family have key roles in regulating T lymphocyte activation and tolerance. These pathways are very attractive therapeutic targets for human cancers including breast cancer. Gene polymorphisms of B7x (B7-H4/B7S1), PD-1 (CD279), and CTLA-4 (CD152) are associated with increased risk of developing breast cancer although the underlying mechanisms are unclear. In human breast cancer microenvironment, up-regulation of coinhibitory B7/CD28 members B7x, B7-H3 (CD276), and PD-L1 (B7-H1/CD274) on tumor cells as well as PD-1 and PD-L1 on tumor-infiltrating immune cells are emerging as immune evasion pathways. Chemotherapy can affect the expression of these molecules, and therefore may dampen the immune response against breast cancer. Immunotherapy targeting T cell coinhibition as monotherapy or combined with standard therapies are in early stages of clinical development, but hold great promise for treatment of human breast cancer.
Indexed as
Identifiers
23114578PMC4107447W150346066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.